Brokers Set Expectations for MPLT Q1 Earnings

Maplight Therapeutics, Inc. (NASDAQ:MPLT) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Maplight Therapeutics in a research report issued on Monday, May 4th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.98) per share for the quarter. HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for Maplight Therapeutics’ current full-year earnings is ($3.87) per share. HC Wainwright also issued estimates for Maplight Therapeutics’ Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($1.21) EPS, FY2026 earnings at ($4.34) EPS, Q1 2027 earnings at ($1.35) EPS, Q2 2027 earnings at ($1.40) EPS, Q3 2027 earnings at ($1.30) EPS, Q4 2027 earnings at ($1.22) EPS and FY2027 earnings at ($5.25) EPS.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, March 26th. The company reported ($2.47) EPS for the quarter, missing the consensus estimate of ($1.05) by ($1.42).

A number of other equities analysts have also recently issued reports on MPLT. TD Cowen initiated coverage on Maplight Therapeutics in a report on Tuesday, April 7th. They set a “buy” rating on the stock. Canaccord Genuity Group initiated coverage on shares of Maplight Therapeutics in a research report on Thursday, March 19th. They issued a “buy” rating and a $35.00 price target on the stock. Wall Street Zen lowered shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings began coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating for the company. Finally, Needham & Company LLC assumed coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.43.

Maplight Therapeutics Stock Down 2.4%

Shares of Maplight Therapeutics stock opened at $27.92 on Wednesday. The company’s fifty day simple moving average is $22.39. The company has a market cap of $1.19 billion and a PE ratio of -0.70. Maplight Therapeutics has a 52 week low of $12.24 and a 52 week high of $33.28.

Institutional Investors Weigh In On Maplight Therapeutics

Several institutional investors have recently bought and sold shares of the company. Fcpm Iii Services B.V. acquired a new position in Maplight Therapeutics during the 4th quarter worth approximately $56,672,000. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Maplight Therapeutics in the fourth quarter valued at approximately $49,154,000. Goldman Sachs Group Inc. bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth $34,026,000. Nan Fung Group Holdings Ltd acquired a new position in Maplight Therapeutics during the fourth quarter worth $17,060,000. Finally, 5AM Venture Management LLC acquired a new position in Maplight Therapeutics during the fourth quarter worth $16,687,000.

Insider Transactions at Maplight Therapeutics

In other news, insider Anatol Kreitzer sold 45,422 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $29.66, for a total value of $1,347,216.52. Following the sale, the insider directly owned 211,190 shares in the company, valued at $6,263,895.40. The trade was a 17.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director George Pavlov acquired 10,658 shares of Maplight Therapeutics stock in a transaction dated Wednesday, February 18th. The shares were purchased at an average cost of $17.48 per share, with a total value of $186,301.84. Following the completion of the transaction, the director directly owned 10,658 shares of the company’s stock, valued at $186,301.84. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders acquired 39,124 shares of company stock worth $693,846 and sold 148,431 shares worth $4,040,428.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.